Q1 FY27 results: revenue up 11%, PAT up 14%; board approves director continuation

Management Changes View source PDF Explain this filing

BAJAJHCARE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-5.8%Reaction day

₹391.00

prior close

₹390.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.3%-6.1% vs market

Pharmaceuticals peers, median of 165sector+0.1%-5.9% vs sector

On the reaction day the stock moved 6.1 pts less than Nifty Microcap 250 and 5.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-2.7

10m

-5.1

15m

-4.7

30m

-4.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-5.8+0.3-6.1+0.1-5.9

Next day

-16.9-0.9-16.0-1.5-15.4

-18.7-1.5-17.2-2.1-16.6

-17.1-1.1-15.9-2.2-14.9

-18.2+0.2-18.4-1.5-16.7

-18.2-1.1-17.1-2.2-15.9

-16.8-1.2-15.7-2.6-14.2

15d

-16.0+3.1-19.2+0.3-16.4

-17.9+4.5-22.3-0.4-17.4

-14.3+4.5-18.8+1.3-15.6

-17.1-2.2-14.9-5.8-11.4

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Bajaj Healthcare posted Q1 FY27 revenue of Rs 16,563 lakhs, up 11% year on year from Rs 14,884 lakhs. Profit after tax from continuing operations rose to Rs 1,389 lakhs vs Rs 1,217 lakhs. Basic EPS stood at Rs 4.07 vs Rs 3.74. Discontinued operations reported a loss of Rs 19 lakhs. Board approved continuation of independent director Gopalakrishnan Kesavan beyond age 75, subject to shareholder approval. Listing approvals received for 20.79 lakh shares from earlier warrant conversion.

Likely market impact

Steady revenue and profit growth; no major governance change. Watch discontinued ops and pending Genrx acquisition.